# Rick Klausner

> Rick Klausner is a Series A investor at Altos Labs backing Biotechnology. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Altos Labs
- Location: San Francisco Bay Area, United States
- Total investments: 9
- Last investment: Nov 2025
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rick-klausner-b5b953197/

Rick Klausner is a Chief Executive Officer at Lyell Immunopharma.

## Contacts

5 contacts available for Rick Klausner: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/rick-klausner?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $30M–$47M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 56% |
| Therapeutics | 4 | 44% |
| Health Care | 3 | 33% |
| Life Science | 3 | 33% |
| Artificial Intelligence | 2 | 22% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 44% |
| Series B | 1 | 11% |
| Series C | 1 | 11% |
| Series E | 1 | 11% |
| Convertible Note | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 56% |
| Israel | 1 | 11% |
| United Kingdom | 1 | 11% |
| The Netherlands | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hippocratic AI | Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $126M | Series C | Nov 03, 2025 |  |
| Meatable | Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $47M | Series A | Mar 23, 2021 |  |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $50M | Series B | Jan 07, 2021 |  |
| Sonoma Biotherapeutics | Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $30M | Series A | Sep 30, 2020 |  |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation. | $41.5M | Series A | Jun 15, 2020 |  |
| Cero Therapeutics | CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease. | $40M | Series A | Mar 18, 2020 |  |
| Eureka Therapeutics | Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancerantigens.Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California. | $45M | Series E | Mar 17, 2020 |  |
| Sonoma Biotherapeutics | Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $40M | Series A | Feb 06, 2020 |  |
| Wisdo Health | Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $4.1M | Convertible Note | Jun 01, 2018 |  |

9 of 9 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 5 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 2 deals together
- [BlueYard Capital](https://shizune.co/investors/profile/blueyard-capital) — VC Fund, 2 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 2 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together
- [Agronomics](https://shizune.co/investors/profile/agronomics-d560) — VC Fund, 1 deal together

## About Altos Labs

VC Fund · San Francisco, United States

Altos Labs is a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.

4 contacts available at Altos Labs.

| Name | Title | Profile |
| --- | --- | --- |
| Hans Bishop | President and Founder | — |
| Rick Klausner | Chief Scientist and Founder | https://shizune.co/investors/profile/rick-klausner |
| Jennifer Doudna | Director | https://shizune.co/investors/profile/jennifer-a-doudna |
| Monique Covington Moore | Senior Director, Global People Operations | — |

## Similar investors

### Similar industry
- [Goodwater Capital](https://shizune.co/investors/profile/goodwater-capital) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Mobile Apps Angel Investors in Israel](https://shizune.co/investors/mobile-apps-angel-investors-israel)
- [Health Care Angel Investors in Israel](https://shizune.co/investors/health-care-angel-investors-israel)
- [Mobile Apps Investors in Israel](https://shizune.co/investors/mobile-apps-investors-israel)
- [Mobile Angel Investors in Israel](https://shizune.co/investors/mobile-angel-investors-israel)

## FAQ

### What does Rick Klausner invest in?

Rick Klausner invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Rick Klausner's check size?

Rick Klausner typically joins rounds of $30M–$47M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rick Klausner participates in.

### How do I contact Rick Klausner?

Public channels for Rick Klausner include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Rick Klausner last invest?

The most recent investment recorded for Rick Klausner closed in Nov 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co